BRIEF published on 05/31/2024 at 17:03, 2 years 5 months ago Moderna reçoit l'approbation de la FDA américaine pour le vaccin contre le RSV mRESVIA Approbation De La FDA Moderne VRS MRESVIA Vaccin
PRESS RELEASE published on 05/31/2024 at 16:58, 2 years 5 months ago Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R) Moderna gains FDA approval for mRESVIA, a single-dose pre-filled syringe RSV vaccine for adults 60+ to prevent lower respiratory tract disease. Second mRNA product and breakthrough therapy designation FDA Approval Moderna RSV Vaccine MRNA MRESVIA
BRIEF published on 05/22/2024 at 13:05, 2 years 5 months ago Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting Clinical Trials Immunotherapy Moderna ASCO 2024 MRNA-4157
BRIEF published on 05/22/2024 at 13:05, 2 years 5 months ago Moderna annonce que les données seront présentées lors de l'assemblée annuelle 2024 de l'ASCO Immunothérapie Essais Cliniques Moderne ASCO 2024 ARNm-4157
PRESS RELEASE published on 05/22/2024 at 13:00, 2 years 5 months ago Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting Moderna to host an investor event via webcast on June 3 at 6:15 PM CDT. Abstracts on mRNA-4157 for ASCO Annual Meeting. Details on mRNA-4157 (V940) therapy development Webcast Moderna Investor Event MRNA-4157 Neoantigen Therapy
BRIEF published on 05/13/2024 at 13:05, 2 years 5 months ago Moderna Announces Participation in Key Investor Conferences Investor Conferences Healthcare Financial Markets Moderna Webcasts
BRIEF published on 05/13/2024 at 13:05, 2 years 5 months ago Moderna annonce sa participation à des conférences clés pour les investisseurs Marchés Financiers Soins De Santé Conférences Investisseurs Moderne Webdiffusions
PRESS RELEASE published on 05/13/2024 at 13:00, 2 years 5 months ago Moderna to Present at Upcoming Conferences in May/June 2024 Moderna, Inc. to participate in upcoming investor conferences, showcasing its leadership in mRNA medicine and innovative approach to disease treatment. Live webcasts available Investor Conferences Moderna Inc. MRNA Medicine Webcasts Disease Treatment
BRIEF published on 05/02/2024 at 12:35, 2 years 6 months ago Moderna Reports Q1 2024 Financial Performance and Strategic Progress Financial Results MRNA Technology Moderna RSV Vaccine Vaccine Development
BRIEF published on 05/02/2024 at 12:35, 2 years 6 months ago Moderna publie ses résultats financiers et ses progrès stratégiques pour le premier trimestre 2024 Résultats Financiers Technologie ARNm Développement De Vaccins Moderne Vaccin Contre Le VRS
Published on 11/10/2026 at 14:31, 29 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 30 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:00, 1 hour ago Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Published on 11/10/2026 at 14:55, 5 minutes ago Geely Farizon Launches 2027 Model Year SV in Germany, Bringing Integrated Passenger and Commercial Vehicle Services to Local Customers
Published on 11/10/2026 at 14:46, 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 11/10/2026 at 14:00, 1 hour ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 2 au 6 novembre 2026
Published on 11/10/2026 at 14:00, 1 hour ago Guillemot Corporation S.A. | Weekly report share buyback from November 2 to November 6, 2026
Published on 11/10/2026 at 11:02, 3 hours 57 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 11:02, 3 hours 57 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 8 hours ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
